Align Technology (NASDAQ:ALGN) Releases Earnings Results, Beats Estimates By $0.03 EPS

Align Technology (NASDAQ:ALGN) posted its earnings results on Wednesday. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.03, FiscalAI reports. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Align Technology had a net margin of 9.99% and a return on equity of 15.86%. Align Technology’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.61 earnings per share.

Here are the key takeaways from Align Technology’s conference call:

• Q3 revenue reached $1.015 billion, up 1.9% year over year, while clear aligner shipments rose 6.6% to a record 691,000 and doctor submitters reached a record 91,000. Utilization improved 3.4%, with broad international growth and strong DSO performance.
• Profitability improved despite a challenging demand environment: non-GAAP operating margin increased to 24.4%, and non-GAAP EPS rose 7.3% to $2.80. Align also plans to repurchase approximately $500 million of stock in 2026.
• Management lowered its near-term outlook, citing continued consumer softness and weaker capital-equipment demand. Q4 revenue is expected at $1.00 billion-$1.02 billion, with low-single-digit clear aligner volume growth and systems-and-services revenue of $170 million-$180 million; full-year revenue is now projected at $4.11 billion-$4.13 billion.
• Align expects continued clear aligner volume growth and at least 100 basis points of non-GAAP operating-margin expansion in 2027 without assuming a consumer recovery. Scanner unit placements are growing, but revenue is being pressured by lower-priced configurations, leasing, rentals, and other flexible acquisition models.
• CEO Joe Hogan will step down at year-end, with Jennifer Davis, a former Procter & Gamble healthcare executive, becoming CEO and president on December 31. Align also plans to pilot a premium, 3D-printed sports mouth guard through Invisalign providers, expanding the potential use of its printing technology beyond orthodontic appliances.

Align Technology Trading Up 1.1%

Shares of ALGN stock opened at $153.62 on Thursday. Align Technology has a 1 year low of $130.23 and a 1 year high of $200.43. The firm’s 50 day moving average is $150.82 and its 200-day moving average is $168.96. The firm has a market capitalization of $11.00 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 1.66 and a beta of 1.67.

Key Stories Impacting Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. Adjusted earnings were $2.80 per share, above the $2.76–$2.77 consensus, while revenue reached approximately $1.015 billion versus expectations near $1.00 billion. EPS also increased from $2.61 a year earlier. Align Technology Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Clear-aligner demand improved. Clear Aligner revenue rose 4.2% year over year to $839.3 million, while shipments increased 6.6% to 690,635. North American orthodontist shipments also showed signs of a recovery. Align Technology Q3 2026 North America Orthodontist Shipments Finally Turn
• Positive Sentiment: Profitability and capital returns were favorable. Net income increased to $135.0 million from $56.8 million, with a 16.7% GAAP operating margin. Align repurchased roughly 627,300 shares in Q3 and expects to buy back up to $300 million of stock in Q4. Align Technology Q3 Revenue Reaches $1.015 Billion as Net Income Rises
• Neutral Sentiment: CEO succession planning adds a management-transition factor. Align announced a CEO succession plan, which may provide continuity but introduces uncertainty as investors assess future leadership and strategy. Align Technology Announces CEO Succession Plan
• Negative Sentiment: Fourth-quarter guidance was a concern. Align forecast revenue of $1.00 billion to $1.02 billion, reportedly below investor expectations. Imaging Systems and CAD/CAM Services revenue also declined 7.6% year over year to $175.5 million. Align Technology Beats Q3 Sales Expectations but Revenue Guidance Misses

Analyst Ratings Changes

ALGN has been the subject of a number of recent analyst reports. Raymond James Financial reaffirmed a “buy” rating on shares of Align Technology in a report on Monday, October 5th. Stifel Nicolaus cut their price objective on Align Technology from $210.00 to $175.00 and set a “buy” rating for the company in a research report on Friday, October 9th. Evercore lowered Align Technology from an “outperform” rating to an “in-line” rating and set a $155.00 price objective on the stock. in a research note on Monday, October 5th. UBS Group restated a “neutral” rating and set a $189.00 target price on shares of Align Technology in a report on Thursday, July 23rd. Finally, BMO Capital Markets began coverage on Align Technology in a report on Wednesday, July 8th. They set an “outperform” rating and a $209.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $190.93.

About Align Technology

Align Technology, Inc is a global medical device company focused on digital orthodontics and restorative dentistry. Founded in 1997, the company is best known for the Invisalign system, a series of clear, removable aligners designed to gradually move teeth and treat a range of orthodontic conditions.

Align’s products and services also include digital scanning and dental practice solutions. Its iTero intraoral scanners create digital impressions for orthodontic and restorative procedures, while its exocad business develops computer-aided design and computer-aided manufacturing software used by dental laboratories, clinicians and other dental professionals.

The company serves orthodontists, dentists, dental laboratories and patients in numerous markets worldwide.